Category: Business

  • Supreme Power Equipment Limited Secures Orders Worth Rs 113.61 Cr

    Supreme Power Equipment Limited Secures Orders Worth Rs 113.61 Cr

    Chennai (Tamil Nadu) [India], March 18: Supreme Power Equipment Limited (SPEL) (NSE: SUPREMEPWR), one of India’s leading manufacturers of power and distribution transformers, has secured new orders aggregating to approximately 113.61 Cr, reinforcing its strong position in the domestic power equipment sector.

    The Company has received a 35.76 Cr order from Kerala State Electricity Board (KSEB) for the supply of 25 MVA, 110/33 KV power transformers, with execution expected within approximately 14 months.

    Additionally, SPEL has secured orders from Tamil Nadu Power Distribution Company amounting to 6.54 Cr for the supply of 500 KVA / 11 KV distribution transformers, to be executed within approximately 12 months.

    Further strengthening its order book, 71.31 Cr worth of transformer orders from Tamil Nadu Power Distribution Company have been awarded to Danya Electric Company, a partnership firm in which SPEL holds 90% stake. These orders include the supply of distribution transformers across multiple capacities—250 KVA / 11 KV, 63 KVA / 22 KV, 16 KVA / 11 KV, and 100 KVA / 11 KV, with execution timelines ranging from 12 to 18 months.

    With these order wins, the Company continues to witness strong demand from state utilities, highlighting its proven execution track record, product quality, and customer trust.

    The successful commissioning and operationalization of SPEL’s new transformer manufacturing facility significantly enhances its production capacity and operational efficiency. This expanded capability positions the Company to execute large-scale and diversified orders efficiently, while maintaining high standards of quality and timely delivery.

    These developments underline SPEL’s continued growth momentum and its commitment to supporting India’s expanding power infrastructure with reliable and advanced transformer solutions.

    Commenting on the development, Mr. Vee Rajmohan, Chairman and Managing Director of Supreme Power Equipment Limited, said, “We are pleased to secure these significant orders aggregating to over ₹113 Cr from key state utilities, which reflects the continued trust placed in our product quality, execution capabilities, and long-standing relationships. These orders further strengthen our order book visibility and reinforce our positioning in the domestic transformer market.

    Importantly, with the successful operationalization of our new transformer manufacturing facility, we are well-equipped to execute larger and more diverse orders with improved efficiency and shorter turnaround times. This enhanced capacity, coupled with our strong engineering capabilities, positions us well to capitalize on the growing opportunities in India’s power infrastructure sector.”

    Disclaimer: This article is for informational purposes only and does not constitute financial advice.

  • Cupid Limited Announces Development of Nitrile Female Condom Targeting Global Monopoly Segment and Strategic Branding Alignment: “Made in India” with “Japanese Quality”

    Cupid Limited Announces Development of Nitrile Female Condom Targeting Global Monopoly Segment and Strategic Branding Alignment: “Made in India” with “Japanese Quality”

    Mumbai (Maharashtra) [India], March 18: Cupid Limited (BSE: 530843 | NSE: CUPID), Cupid Limited, India’s leading manufacturer and exporter of male and female condoms, today announced the commencement of its development programme for a Nitrile (NBR) Female Condom, aimed at entering and diversifying the currently single supplier global nitrile female condom market. The Company also announced a strategic branding alignment centered on the proposition “Made in India” with “Japanese Quality,” reinforcing its commitment to combining India’s strong manufacturing capabilities with globally recognized standards of precision, reliability, and product excellence.

    Addressing a Long-Standing Single-Supplier Market

    The global female condom market was estimated to be valued at approximately USD 770 million in 2024 and is projected to exceed USD 1.2 billion by 2030. Within this market, the nitrile female condom segment, a premium latex-free category, has historically been supplied by only one manufacturer worldwide, which produces the FC2 Female Condom. With the increasing demand from global procurement agencies for supply diversification, Cupid’s entry into nitrile female condom manufacturing represents a significant strategic opportunity.

    Purpose-Built Dual-Polymer Manufacturing Facility

    Cupid’s new manufacturing facility, part of the Company’s previously announced expansion programme, has been architecturally and technically designed to accommodate dual-polymer dipping lines operating concurrently. This configuration allows the facility to manufacture:

    • Natural Rubber Latex (NRL) condoms
    • Nitrile Butadiene Rubber (NBR) condoms

    on dedicated production lines within the same facility, ensuring no cross-contamination and optimal production efficiency. With this development, Cupid becomes the only condom manufacturer in India with integrated dual-polymer dipping capability, enabling the Company to serve:

    • the established NRL male condom market
    • the NRL female condom market
    • the premium nitrile female condom segment

    Upon full commissioning, the expanded new facility is expected to support annual production capacity of approximately:

    • 1.25 billion male condoms
    • 125 million female condoms

    Development Programme and Technical Approach

    Cupid has initiated a structured research and development programme for the nitrile female condom, supported by international technical expertise with deep domain experience in:

    • NBR compound formulation
    • dipping technology
    • female condom design engineering

    The programme will focus on formulation optimization, coagulant engineering, dipping parameters, and comprehensive validation testing, in accordance with ISO 25841:2017 standards for female condoms.

    Cupid already possesses a strong regulatory foundation in the segment, with its NRL-based female condom currently holding WHO/UNFPA prequalification and being supplied to more than 50 countries globally.

    Strategic Rationale

    Cupid’s entry into the nitrile female condom segment is driven by several compelling strategic factors:

    1. Supply Diversification

    Global procurement agencies such as UNFPA and national ministries of health have long sought alternative suppliers to reduce reliance on a single manufacturer.

    2. Premium Product Segment

    Nitrile female condoms typically command 25–35% higher prices than latex alternatives due to their key advantages:

    • Latex-free material (suitable for latex-allergic users)
    • Thinner construction
    • Lower odor profile
    • More natural heat conduction

    3. Technical and Regulatory Barrier to Entry

    The specialized raw material supply chain, formulation expertise, and regulatory requirements create significant barriers to entry. Cupid’s existing technical capabilities and global distribution experience provide a strong platform to compete effectively in this segment.

    Commenting on the Development, Mr. Durgesh Garg, Chief Operating Officer said, “For over two decades, the nitrile female condom segment has largely been served by a single supplier. This has limited procurement flexibility for global health agencies and restricted access to latex-free protection for many women worldwide. Cupid is uniquely positioned to address this gap.

    Our new manufacturing plant has been purpose-designed from the ground up to support simultaneous dipping of two distinct polymer systems Natural Rubber Latex and Nitrile. This dual-polymer capability will allow us to offer global procurers a credible, quality-assured second source for nitrile female condoms.”

    Additionally, Cupid Limited has also announced a strategic branding alignment centered on the powerful proposition “Made in India” with “Japanese Quality.”

    This initiative reflects Cupid Limited’s commitment of combining India’s strong manufacturing capabilities with globally recognized standards of precision, reliability, and product excellence. The initiative has been made possible through a collaboration with Asia’s oldest latex condom manufacturing company, further strengthening Cupid’s technological capabilities and reinforcing its global positioning.

    The new branding focus is designed to resonate strongly with both Indian consumers and the Company’s valued corporate OEM (Original Equipment Manufacturer) partners worldwide. The initiative also marks a milestone in Cupid Limited’s 28-year journey in condom manufacturing, underscoring the Company’s continued focus on quality, reliability, and innovation.

    Through this strategic positioning, Cupid Limited aims to achieve multiple objectives:

    For Cupid Brand Consumers
    The initiative is intended to strengthen consumer confidence in the Cupid brand, aligning Indian consumers with an elevated standard of trust, safety, and product reliability.

    For Corporate OEM Customers
    Cupid Limited will extend the same assurance of quality and reliability to its global OEM partners, further reinforcing its position as a dependable and trusted global supplier of high-quality condom products.

    With this initiative, Cupid Limited continues to strengthen its position as a trusted global manufacturer delivering world-class quality products, while also highlighting India’s growing role as a reliable manufacturing hub for healthcare and personal wellness products.

    Commenting on the Development, Mr. Dhruba Goswami, Business Development Head said, “For over two decades, the nitrile female condom segment has largely been served by a single supplier. This has limited procurement flexibility for global health agencies and restricted access to latex-free protection for many women worldwide. Cupid is uniquely positioned to address this gap.

    Our new manufacturing plant has been purpose-designed from the ground up to support simultaneous dipping of two distinct polymer systems Natural Rubber Latex and Nitrile. This dual-polymer capability will allow us to offer global procurers a credible, quality-assured second source for nitrile female condoms.”

    Disclaimer: This article is for informational purposes only and does not constitute financial advice.

  • Chandan Healthcare Enters Maharashtra and West Bengal; Launches Mumbai, Kolkata & Kota Diagnostic Centres

    Chandan Healthcare Enters Maharashtra and West Bengal; Launches Mumbai, Kolkata & Kota Diagnostic Centres

    lucknow (Uttar Pradesh) [India], March 19:: Chandan Healthcare Limited (NSE – CHANDAN), – Chandan Healthcare Limited, one of the leading diagnostic and healthcare service providers in North India, has expanded its presence with the launch of new diagnostic centres in Mumbai and Kolkata, marking its entry into Maharashtra and West Bengal. The Company has also commenced diagnostic operations in Kota (Rajasthan), further strengthening its growing network across India.

    The Mumbai and Kolkata centres are equipped to offer comprehensive diagnostic services, including pathology and blood investigations, along with advanced tests such as TMT, ECG, EEG, and PFT. These centres are designed to cater to a wide range of patient requirements while also supporting diagnostic needs of associated partner centres across the network, enabling integrated and efficient service delivery.

    The Company plans to further enhance capabilities at these facilities by introducing additional diagnostic services such as X-Ray and Bone Mineral Density (BMD) in due course, strengthening its service portfolio and improving overall diagnostic accessibility.

    In addition, Chandan Healthcare has commenced diagnostic operations in Kota (Rajasthan) as part of its ongoing rollout under the previously announced five-year strategic partnership with Jeena Sikho Lifecare Limited. As the exclusive diagnostic partner for Jeena Sikho hospitals and clinics, the Company will continue to expand diagnostic services across additional facilities under this collaboration.

    This expansion is expected to strengthen the Company’s overall diagnostic network, improve access to quality healthcare services, and support higher patient volumes. The launch of centres in Mumbai and Kolkata enhances its presence in key urban markets, while the Kota operations support execution of its partnership-led expansion strategy and long-term growth plans.

    Commenting on the development, Mr. Amar Singh, Promoter and Managing Director of Chandan Healthcare Limited, said, “We are pleased to expand our presence into Maharashtra and West Bengal, along with the rollout of operations under the Jeena Sikho partnership in Kota. This aligns with our strategy to build a scalable and integrated diagnostic network

    We remain focused on enhancing accessibility, strengthening our service capabilities, and expanding our presence across high-growth regions. At the same time, we will continue to invest in expanding our diagnostic offerings and supporting our partner network to deliver consistent and high-quality healthcare services.”

    If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.

  • HEC Infra Projects Limited Secures Rs 36.50 Cr EPC Order for 10.4 MW Solar Power Plant

    HEC Infra Projects Limited Secures Rs 36.50 Cr EPC Order for 10.4 MW Solar Power Plant

    Ahmedabad (Gujarat) [India], March 18: HEC Infra Projects Limited (HEC Infra Projects Limited, The Company), (NSE Code: HECPROJECT), one of the leading EPC players specialising in Electrical, Mechanical, and Instrumentation works, is pleased to announce that the Company has secured a work order worth approximately 36.50 Cr from M/S Siemens Financial Services Private Limited. The order has been awarded for the development of a 10.4 MW Solar Power Plant Generation System.

    The scope of the project includes engineering, procurement and construction of the solar power plant, covering the installation and commissioning of the complete solar power generation system along with associated infrastructure. The project is scheduled to be completed within a period of 6 months.

    This project reflects the increasing demand for renewable energy infrastructure and highlights the growing opportunities in India’s solar power sector driven by the country’s transition towards clean and sustainable energy sources.

    Going forward, HEC Infra Projects Limited intends to actively participate in similar EPC opportunities in the renewable energy sector while continuing to expand its presence across solar and power infrastructure projects in India.

    On the receipt of the order, Mr. Gaurang Shah, Managing Director of HEC Infra Projects Limited said, “We are pleased to secure this EPC order for the development of a 10.4 MW Solar Power Plant Generation System. The project represents an important addition to our project portfolio and reflects the growing opportunities emerging in the solar power sector.

    We remain committed to executing the project within the stipulated timeline of 6 months while maintaining high standards of quality and operational efficiency. With India continuing to expand its solar power capacity as part of the clean energy transition, the sector presents strong long-term growth potential.”

    Disclaimer: This article is for informational purposes only and does not constitute financial advice.

  • Arvore Healthcare Reinforces Legacy Leadership in Orthopedic Implants, Strengthening Its Position as a Trusted Partner to Surgeons Across India and Global Markets

    Arvore Healthcare Reinforces Legacy Leadership in Orthopedic Implants, Strengthening Its Position as a Trusted Partner to Surgeons Across India and Global Markets

    New Delhi [India], March 19:  Arvore Healthcare, a long-established and trusted name in the Indian orthopedic industry, continues to reinforce its leadership with a deeply integrated and time-tested Orthopedic Implants Division, built on years of clinical trust, engineering excellence, and consistent surgical performance.

    With a strong legacy of serving hospitals and surgeons across the country, Arvore Healthcare has evolved into a comprehensive solutions provider spanning Orthopedic Trauma Implants (Nails, Plates, and Screws), Arthroscopy, Spine Implants, and Arthroplasty systems—delivering reliability that has stood the test of time in operating rooms.

    A Proven Backbone in Orthopedic Trauma Care

    Arvore’s Trauma Implant portfolio has long been regarded as a dependable choice among orthopedic surgeons, offering a wide range of intramedullary nails, anatomically contoured plates, and high-precision screws. Engineered for consistent fixation strength and predictable outcomes, these systems have been extensively used in managing complex fractures across diverse clinical settings.

    The division’s continued focus on design refinement and metallurgical precision ensures implants that perform reliably under demanding surgical conditions—reinforcing surgeon confidence built over years of usage.

    Trusted Solutions in Arthroscopy and Sports Medicine

    In the evolving domain of minimally invasive orthopedic procedures, Arvore Healthcare’s Arthroscopy range reflects a mature understanding of surgical needs developed over time. The company offers advanced solutions for ligament reconstruction, soft tissue fixation, and joint stabilization—supporting surgeons in achieving precision with minimal tissue disruption.

    With a track record of dependable performance, Arvore’s arthroscopy systems contribute to faster recovery cycles and improved patient satisfaction.

    Comprehensive Spine Portfolio Backed by Clinical Confidence

    Arvore Healthcare’s Spine Implants division has steadily built credibility by delivering consistent results in spinal fixation and stabilization procedures. Designed to address degenerative conditions, trauma cases, and deformity corrections, these systems combine structural strength with surgical versatility.

    The company’s long-standing engagement with spine specialists has enabled continuous product evolution aligned with real-world clinical demands.

    Arthroplasty Systems Designed for Long-Term Performance

    In joint replacement, Arvore’s Arthroplasty solutions for hip and knee procedures are known for their durability, anatomical precision, and sustained clinical outcomes. Developed through years of experience and surgeon feedback, these systems are designed to restore mobility while ensuring long-term implant performance.

    Legacy of Trust, Vision for the Future

    Arvore Healthcare’s sustained presence in the orthopedic sector is anchored in its commitment to quality manufacturing, stringent compliance with international standards, and deep-rooted relationships with the medical fraternity.

    A company spokesperson stated, “Our strength lies in the trust we have built over the years. Surgeons rely on Arvore not just for products, but for consistency, reliability, and clinical assurance. As we move forward, we continue to build on this legacy while expanding our global reach.”

    With an expanding footprint across international markets and a reputation grounded in performance, Arvore Healthcare stands as a symbol of enduring trust and capability in orthopedic implants—where experience meets innovation to deliver dependable surgical outcomes.

    About Arvore Healthcare Arvore Healthcare is a well-established orthopedic solutions provider with a strong presence in India and growing global markets. Known for its quality-driven approach and long-standing industry experience, the company continues to support surgeons with reliable, high-performance medical devices across key orthopedic segments.

    If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.

  • Pure Nutrition Comes Onboard as the Official Sports Nutrition Partner for IPL Frontrunner – Chennai Super Kings

    Pure Nutrition Comes Onboard as the Official Sports Nutrition Partner for IPL Frontrunner – Chennai Super Kings

    Mumbai (Maharashtra) [India], March 18: In a masterstroke that brings together two behemoths from the fields of cricket and nutrition, Pure Nutrition, one of India’s fastest-growing sports and wellness nutrition brands, has officially announced its partnership with the Chennai Super Kings (CSK). Pure Nutrition will come onboard as the Official Sports Nutrition Partner of the franchise. The landmark association between one of cricket’s most celebrated teams and a revolutionary brand defined by its commitment to clean, science-backed nutrition solutions that empower athletes and fitness enthusiasts. The partnership is defined by the shared values of consistency, innovation and sporting brilliance.

    Pure Nutrition views this collaboration as a natural alignment between two brands that share an uncompromising pursuit of excellence. Further, the brand’s decision to back the team was rooted in the understanding of the peak physical conditioning, rapid recovery and sustained mental focus across gruelling tournament schedules that modern cricket demands. Pure Nutrition’s presence is emblematic of the pivotal role nutrition plays in enabling elite athletic performance.

    As an extension of this collaborationPure Nutrition has launched an exclusive CSK co-branded product line. Each product in this range has been crafted with carefully selected, high-quality ingredients designed to support strength, endurance, recovery, and overall athletic wellbeing. The range includes Whey Protein, Creatine, Lean Meal Shake for Weight Management, Pre-Workout, BCAA, Mass Gainer, L-Carnitine Liquid, and Yeast Protein.

    Commenting on the collaboration, Sushil Khaitan, Founder, Pure Nutrition, said: “Partnering with Chennai Super Kings is a proud milestone for us. CSK stands for discipline, resilience and excellence — values we share at Pure Nutrition. Together, we’re making a powerful statement about the role nutrition plays in building champions.”

    “Nutrition is central to performance, recovery and longevity in elite sport. Our partnership with Chennai Super Kings gives us a powerful platform to advocate for performance-driven nutrition that makes a real difference to athletes at every level,” added Anmol Choubey, Director & COO, Pure Nutrition.

    KS Vishwanathan, Managing Director, Chennai Super Kings, commented, “At Chennai Super Kings, we believe sustained performance at the highest level is built on preparation, discipline and the right support systems. Nutrition plays a critical role in enabling athletes to perform well. We are delighted to partner with Pure Nutrition, a brand that shares our commitment to excellence and scientific approach to performance. Together, we look forward to promoting the importance of clean, effective sports nutrition to athletes and fans alike.” 

    About Pure Nutrition

    Pure Nutrition is a leading Indian sports and wellness nutrition brand committed to the philosophy of “Pure Ingredients, Real Results.” The brand offers a comprehensive portfolio of scientifically formulated supplements and functional nutrition products designed to support performance, recovery, and overall well-being for athletes, fitness professionals and health-conscious individuals. Pure Nutrition’s products are available across major e-commerce, quick commerce platforms and retail outlets throughout India.

    About Chennai Super Kings

    Chennai Super Kings (CSK) is one of the most iconic and successful franchises in the Indian Premier League (IPL), renowned for its consistent excellence, elite leadership, and passionate global fan base. With multiple IPL titles to its name, CSK is celebrated for its culture of professionalism, strategic brilliance, and an enduring legacy that has made it synonymous with cricketing greatness in India and across the world.

    Website: www.purenutrition.in

    If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.

  • Ekta World Introduces Ekta Victoria, a Premium Residential Address Near Pali Hill

    Ekta World Introduces Ekta Victoria, a Premium Residential Address Near Pali Hill

    The image shared is a rendered image. MAHARERA Registration Number: PR1180002502359

    Mumbai (Maharashtra) [India], March 18: Ekta World has unveiled its newest boutique residential development, Ekta Victoria, located on St. Alexious Road in Bandra West, one of Mumbai’s most prestigious neighbourhoods. Strategically positioned in the heart of the vibrant Bandra suburb and close to Pali Hill, this project from Ekta World blends timeless architectural inspiration with contemporary luxury living.

    Ekta Victoria is an exclusive 11-storey residential tower that reflects the elegance and charm of colonial architecture, lending the development a distinctive aesthetic identity within the Bandra skyline. Ekta Victoria offers a rare balance of tranquillity and accessibility being part of a neighbourhood known for its greenery and peaceful residential character while being within easy reach of Bandra West’s vibrant lifestyle hubs, dining destinations, retail outlets and cultural hotspots. The project has achieved its RERA registration marking a significant milestone, as Ekta World reinforces its commitment to transparency and regulatory compliance. The development is expected to be ready for possession in 2028.

    Spacious homes complemented by world-class amenities lie at the heart of this project, designed to attract affluent families to one of Mumbai’s most sought-after residential neighbourhoods. Ekta Victoria caterers to the growing preference among urban families for larger and more flexible living spaces, with spacious 2 & 3 Bed residences ranging from 904 sq. ft. to 1,242 sq. ft.  Each apartment has a Vaastu compliant design and includes a spacious deck along with an impressive 12-foot ceiling height, creating an enhanced sense of openness and natural light. The additional bedroom offers versatility and can easily be adapted to suit evolving lifestyle needs, whether as a guest room, home office, children’s playroom or a personal fitness space.

    Residents of Ekta Victoria will have access to a carefully curated range of lifestyle amenities designed to support both wellness and recreation. These include a fitness centre, outdoor gym and yoga zone, sky lounge, indoor games area, children’s play zone and a dedicated walking path. The development will also feature a grand entrance lobby and ample parking facilities, reflecting the developer’s focus on detailed planning and convenience for residents.

    Commenting on the new Bandra project launch, Vivek Mohanani, CEO & Managing Director of Ekta World said, “Bandra has always been among aspirational residential locations, where heritage, culture and modern urban life come together. Ekta Victoria is part of our effort to creating an intimate residential community that delivers strongly on architectural character and functional design. The aim behind this is to offer homes that evolve with the needs of modern families while preserving the charm and exclusivity that Bandra is about.”

    With more than 38 years of experience in the real estate sector, Ekta World continues to strengthen its reputation for delivering high-quality developments that combine thoughtful design, premium lifestyle features and enduring value for homebuyers.  As the brand sharpens its focus on redevelopment opportunities across the Bandra, Khar and Santacruz (BKS) belt, Ekta Victoria stands as another step in its effort to revitalise established neighbourhoods through well-designed residential developments.

    Visit www.ektaworld.com for more info.

    If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.

  • Tipco Engineering India Limited IPO Opens on March 23, 2026

    Tipco Engineering India Limited IPO Opens on March 23, 2026

    Mumbai (Maharashtra) [India], March 18: Tipco Engineering India Limited is an integrated engineering and manufacturing company engaged in the design, fabrication, assembly, and supply of industrial process machinery proposes to open its Initial Public Offering on March 23, 2026, aiming to raise ₹ 60.55 Crores (at upper price band) with shares to be listed on the BSE SME.

    The issue size is 68,03,200 equity shares with a face value of ₹ 10 each with a price band of ₹ 84 – ₹ 89 Per Share.

    Equity Share Allocation

    • Anchor Portion – Up to 17,20,000 Equity Shares
    • Qualified Institutional Buyer – Not more than 11,56,800 Equity Shares (excluding Anchor portion)
    • Non-Institutional Investors – Not less than 8,73,600 Equity Shares
    • Individual Investors – Not less than 20,32,000 Equity Shares
    • Market Maker – Up to 10,20,800 Equity Shares

    The net proceeds from the IPO will be utilized for Repayment/prepayment of all or certain of our borrowings, working capital requirements, and the general corporate purposes. The anchor bidding is on Friday, March 20, 2026. The Issue will open on Monday, March 23, 2026 and will close on Wednesday, March 25, 2026.

    The Book Running Lead Manager to the Issue is Smart Horizon Capital Advisors Private Limited, and the Registrar is Maashitla Securities Private Limited.

    Mr. Ritesh Sharma, Promoter, Chairman and Managing Director of Tipco Engineering India Limited expressed, “we are committed to delivering high-quality, customized process engineering and manufacturing solutions across industries such as paint and Coating, chemicals, printing and packaging, metal, Constructions and Infrastructure ,. Our integrated in-house capabilities in design, engineering, manufacturing, and testing enable us to deliver reliable and scalable solutions to our customers.

    Since our incorporation in 2021, we have built strong customer relationships, executed numerous projects across India, and developed a diversified presence across industries. Our focus on engineering excellence, quality standards, and operational efficiency has helped us build a strong foundation for sustainable growth.

    The proposed IPO marks an important milestone in our growth journey. The funds raised will primarily support our growing working capital requirements and strengthen our ability to execute larger and more complex projects. This will enable us to scale operations, enhance delivery capabilities, and capitalize on emerging opportunities across the process equipment industry.”

    Mr. Parth ShahDirector of Smart Horizon Capital Advisors Private Limited said “We are pleased to be associated with the proposed IPO of TIPCO Engineering India Limited. The company has built a strong foundation in the process engineering and industrial equipment space with its integrated capabilities across design, manufacturing, and execution of high value projects.

    With a diversified customer base, growing order book, and presence across multiple end-use industries, the company is well positioned to benefit from increasing demand for specialized process equipment in India. We believe the IPO will support the company’s next phase of growth and provide investors an opportunity to participate in its long-term value creation journey.”

    Disclaimer: This article is for informational purposes only and does not constitute financial advice.

  • Speciality Medicines Limited IPO Opens on March 20, 2026

    Speciality Medicines Limited IPO Opens on March 20, 2026

    Mumbai (Maharashtra) [India], March 18: Speciality Medicines Limited, a company engaged in the marketing and distribution of specialty pharmaceutical products across multiple therapeutic areas, proposes to open its Initial Public Offering on Friday, March 20, 2026 aiming to raise ₹ 29.14 Crore (At Upper Price Band), with shares to be listed on the BSE SME platform.

    The issue size is 23,50,000 equity shares at a face value of ₹ 10 each with a price band of
    ₹ 117- ₹ 124 Per Share.

    Equity Share Allocation

    • Qualified Institutional Buyer – Up To 21,000 Equity Shares
    • Non-Institutional Investors – Up To 10,89,000 Equity Shares
    • Retail Individual Investors – Up To 10,90,000 Equity Shares
    • Market Maker – Up To 1,50,000 Equity Shares

    The net proceeds from the IPO will be utilized for Setting up of Research and Development (R&D) Centre, Product Registration in International Markets and Product Development for sale in international markets, Funding for Marketing and Promotional Activities, To Meet Working Capital Requirements and General Corporate Purposes. The issue will open on Friday, Mar 20, 2026 and will close on Tuesday, Mar 24, 2026.

    The Book Running Lead Manager to the Issue is Unistone Capital Private Limited, The Registrar to the Issue is Skyline Financial Services Private Limited.

    Mr. Parth Goyani, Chairman & Managing Director of Speciality Medicines Limited expressed, “We have built Speciality Medicines Limited with a strong focus on providing access to high-value specialty pharmaceutical products across critical therapeutic areas such as oncology, immunology and neurology. Over the years, our distribution strength, customer relationships and product portfolio have helped us expand our presence across more than 20 states in India and several international markets.

    The proposed IPO marks an important milestone in our growth journey. The proceeds will primarily be utilized to establish a dedicated Research & Development center, strengthen product registrations in international markets, expand our marketing and promotional reach, and support working capital requirements. These initiatives will enable us to broaden our product portfolio, deepen our global footprint and enhance our ability to deliver innovative solutions for complex chronic conditions.

    We believe this capital infusion will significantly strengthen our capabilities and position the company for sustainable long-term growth.”

    Mr. Brijesh Parekh, Founder & Director of Unistone Capital Private Limited said, “We are delighted to be associated with the proposed IPO of Speciality Medicines Limited and to support the company in this important milestone of its growth journey. The company has built a strong presence in the specialty pharmaceuticals segment with a diversified portfolio products and a growing footprint across India and international markets.

    The company’s focus on high-value therapeutic areas and its strong distribution network position it well to capture opportunities in the rapidly expanding specialty pharmaceutical market.

    The proceeds from the IPO will support the establishment of a dedicated R&D center, expansion of product registrations in international markets, strengthening of marketing initiatives, and funding of working capital requirements. We believe these initiatives will further enhance the company’s growth prospects and help it scale its operations in both domestic and global markets.”

    Disclaimer: This article is for informational purposes only and does not constitute financial advice.

  • Ahmed Al Maghribi Unveils Exclusive Eid Gifting

    Ahmed Al Maghribi Unveils Exclusive Eid Gifting

    New Delhi [India], March 18: As Eid approaches, a festival globally celebrated for reflection, devotion, and generosity, Ahmed Al Maghribi Perfumes invites you to honour traditions and deepen connections through the universal language of fragrance. Throughout the Middle East, South Asia, and beyond, scent remains an enduring symbol of welcome, respect, and unity, woven into the very fabric of Eid rituals and gatherings.

    Rooted in the legacy of Arabic perfumery, Ahmed Al Maghribi Perfumes has emerged as a beacon of heritage-infused innovation. With a vision to elevate traditional Middle Eastern scent profiles for a discerning global audience, the brand is lauded for its artisanal craftsmanship, finest raw materials, and signature compositions that transcend generations. Every fragrance is a testament to the house’s commitment to balancing timeless tradition with contemporary elegance, reinforcing its position as a global leader in luxury perfumery.

    To commemorate this festive occasion, Ahmed Al Maghribi Perfumes is delighted to announce an exclusive 20% Eid offer across a handpicked selection of its most coveted fragrances. This initiative offers patrons an exceptional opportunity to express appreciation and affection through gifts that embody sophistication and meaning. The Eid Gifting Edit features standout creations such as Blue By Ahmed, a luminous blend of aquatic freshness and musky warmth; Kaaf (Extrait de Parfum), a powerful composition of woods, amber, and spice for those who seek distinction; Marj, a delicately oriental fragrance interweaving florals with subtle sweetness; and Oud & Roses, an iconic fusion of opulent oud and romantic rose, epitomising the artistry of Middle Eastern perfumery.

    Kafeel Ahmed, Chairman, Founder, and Master Perfumer, remarked: “Eid is a time that calls us to gratitude, generosity, and reflection. Fragrance remains at the heart of our cultural celebrations, serving as an emblem of hospitality and personal expression. With this initiative, our goal is to enable our community to share expertly crafted scents that enrich the spirit of togetherness and leave an indelible impression.”

    Available exclusively for a limited period, this 20% offer underscores Ahmed Al Maghribi Perfumes’ dedication to making luxury accessible, while championing the values of tradition, generosity, and community that define this festival.

    About Ahmed Al Maghribi

    Established in 2000 in Dubai by Kafeel Ahmed, Ahmed Al Maghribi Perfumes has grown from a single home-based operation into a globally recognised luxury fragrance house with over 190+ branches across the GCC and presence in more than 90 countries. Rooted in Arabian perfumery heritage, the brand blends traditional craftsmanship with contemporary innovation to create distinctive, high-quality scents that resonate worldwide.

    Digital Footprints

    Website: https://www.ahmedalmaghribi.co.in/

    Instagram: https://www.instagram.com/ahmedalmaghribiperfumeindia

    If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.